T cell engagers (TCE) such as chimeric antigen receptor (CAR) T cell therapy and bispecific
antibodies (BiAbs) for the treatment of multiple myeloma (MM) have significantly improved …

Introduction Multiple new drugs have been approved over the past 5 years for the treatment
of relapsed/refractory multiple myeloma (RRMM), and these are being increasingly widely …

Despite concerns about an increased risk of adverse outcomes following coronavirus
disease (COVID‐19) in multiple myeloma patients treated with anti‐CD38 Abs, the impact of …

The use of lenalidomide in frontline therapy for patients with newly diagnosed multiple
myeloma (MM) has increased the number of those who become refractory to lenalidomide at …

The present study is an overview of systematic reviews focusing on adverse events of
antimyeloma treatments. It provides a systematic description of adverse events as they are …

Preclinical and clinical data demonstrate synergy between belantamab mafodotin (belamaf)
and immunomodulatory drugs with limited overlapping toxicities. We investigated the safety …

Advancements in treatments have significantly improved the prognosis for mantle cell
lymphoma (MCL), and there is a growing population of survivors with an increased …

Simple Summary Immunoglobulin (Ig) replacement therapy (IgRT) consists of the
administration of low-doses human polyclonal Igs for the treatment of primary and secondary …

Background Daratumumab and isatuximab are anti-CD38 monoclonal antibodies indicated
for the treatment of multiple myeloma. These agents can increase the risk of infectious …

Simple Summary Multiple myeloma (MM) represents the second most common
hematological malignancy, but its diagnosis can be significantly delayed since symptoms …